Pfizer Inc. $PFE Shares Acquired by B.O.S.S. Retirement Advisors LLC

B.O.S.S. Retirement Advisors LLC grew its position in Pfizer Inc. (NYSE:PFE) by 5.0% in the 2nd quarter, Holdings Channel.com reports. The fund owned 11,450 shares of the biopharmaceutical company’s stock after acquiring an additional 543 shares during the quarter. B.O.S.S. Retirement Advisors LLC’s holdings in Pfizer were worth $278,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also modified their holdings of PFE. GKV Capital Management Co. Inc. acquired a new stake in shares of Pfizer in the first quarter valued at approximately $27,000. North Capital Inc. acquired a new stake in shares of Pfizer in the first quarter valued at approximately $28,000. Bayforest Capital Ltd acquired a new stake in shares of Pfizer in the first quarter valued at approximately $28,000. Horizon Financial Services LLC purchased a new stake in Pfizer during the 1st quarter valued at approximately $35,000. Finally, WPG Advisers LLC purchased a new stake in Pfizer during the 1st quarter valued at approximately $35,000. 68.36% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several analysts have commented on PFE shares. Citigroup upped their price objective on Pfizer from $25.00 to $26.00 and gave the company a “neutral” rating in a research note on Wednesday, August 6th. UBS Group reaffirmed a “neutral” rating and set a $28.00 price objective on shares of Pfizer in a research note on Wednesday. Bank of America upped their price objective on Pfizer from $27.00 to $28.00 and gave the company a “neutral” rating in a research note on Wednesday, August 6th. Morgan Stanley upped their price objective on Pfizer from $32.00 to $33.00 and gave the company an “equal weight” rating in a research note on Wednesday, August 6th. Finally, Wall Street Zen downgraded Pfizer from a “buy” rating to a “hold” rating in a research note on Sunday, September 28th. Two investment analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating, eleven have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, Pfizer has an average rating of “Hold” and a consensus target price of $28.29.

Pfizer Stock Performance

Shares of PFE stock opened at $27.08 on Friday. The company has a market cap of $153.94 billion, a price-to-earnings ratio of 14.40, a price-to-earnings-growth ratio of 0.88 and a beta of 0.55. The stock has a 50 day simple moving average of $24.62 and a 200-day simple moving average of $24.14. Pfizer Inc. has a 12-month low of $20.92 and a 12-month high of $30.43. The company has a current ratio of 1.16, a quick ratio of 0.85 and a debt-to-equity ratio of 0.65.

Pfizer (NYSE:PFE) last issued its earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.58 by $0.20. The business had revenue of $14.65 billion during the quarter, compared to the consensus estimate of $13.43 billion. Pfizer had a return on equity of 21.42% and a net margin of 16.84%.The company’s revenue for the quarter was up 10.3% on a year-over-year basis. During the same period in the prior year, the business posted $0.60 EPS. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. On average, equities analysts forecast that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.